CN1390547A - 对由局部缺血引发的组织损伤的治疗 - Google Patents

对由局部缺血引发的组织损伤的治疗 Download PDF

Info

Publication number
CN1390547A
CN1390547A CN02120397A CN02120397A CN1390547A CN 1390547 A CN1390547 A CN 1390547A CN 02120397 A CN02120397 A CN 02120397A CN 02120397 A CN02120397 A CN 02120397A CN 1390547 A CN1390547 A CN 1390547A
Authority
CN
China
Prior art keywords
pyridazin
benzenesulfonyl
compound
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN02120397A
Other languages
English (en)
Chinese (zh)
Inventor
B·L·米拉里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1390547A publication Critical patent/CN1390547A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN02120397A 2001-05-24 2002-05-24 对由局部缺血引发的组织损伤的治疗 Pending CN1390547A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29339301P 2001-05-24 2001-05-24
US60/293,393 2001-05-24

Publications (1)

Publication Number Publication Date
CN1390547A true CN1390547A (zh) 2003-01-15

Family

ID=23128899

Family Applications (1)

Application Number Title Priority Date Filing Date
CN02120397A Pending CN1390547A (zh) 2001-05-24 2002-05-24 对由局部缺血引发的组织损伤的治疗

Country Status (15)

Country Link
US (1) US6872722B2 (https=)
EP (1) EP1260224B1 (https=)
JP (1) JP2002370984A (https=)
KR (1) KR20020090321A (https=)
CN (1) CN1390547A (https=)
AT (1) ATE289510T1 (https=)
AU (1) AU761191B2 (https=)
CA (1) CA2387007A1 (https=)
CZ (1) CZ20021782A3 (https=)
DE (1) DE60203026T2 (https=)
ES (1) ES2236447T3 (https=)
HU (1) HUP0201738A3 (https=)
PL (1) PL354128A1 (https=)
SK (1) SK7332002A3 (https=)
ZA (1) ZA200203985B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DK1961420T3 (da) * 2005-12-16 2012-08-27 Sanwa Kagaku Kenkyusho Co Middel til forebyggelse og behandling af akut nyresvigt
KR20080108465A (ko) * 2006-02-20 2008-12-15 가부시키가이샤산와카가쿠켄큐쇼 뇌졸중에 있어서의 뇌허혈 또는 뇌허혈 재관류 장해의 예방또는 치료제
WO2022197487A1 (en) 2021-03-18 2022-09-22 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH01258671A (ja) * 1987-12-01 1989-10-16 Morishita Pharmaceut Co Ltd 5−(1h−イミダゾール−1−イル)−3(2h)−ピリダジノン誘導体
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
WO1992017446A2 (en) * 1991-03-28 1992-10-15 Pfizer Inc. Pyridazinone acetic acids aldose reductase inhibitors
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
US5506228A (en) * 1995-02-23 1996-04-09 Merck & Co., Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
CN1142148C (zh) * 1997-11-19 2004-03-17 兴和株式会社 新颖的哒嗪衍生物和含有其作为有效成分的药物
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−3−オン誘導体及びこれを含有する医薬
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
CA2442476A1 (en) * 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors

Also Published As

Publication number Publication date
US6872722B2 (en) 2005-03-29
AU761191B2 (en) 2003-05-29
EP1260224B1 (en) 2005-02-23
JP2002370984A (ja) 2002-12-24
DE60203026D1 (de) 2005-03-31
CZ20021782A3 (cs) 2003-03-12
EP1260224A1 (en) 2002-11-27
HUP0201738A2 (hu) 2003-02-28
ES2236447T3 (es) 2005-07-16
HUP0201738A3 (en) 2003-11-28
ATE289510T1 (de) 2005-03-15
US20030008871A1 (en) 2003-01-09
ZA200203985B (en) 2003-11-20
DE60203026T2 (de) 2006-05-04
PL354128A1 (en) 2002-12-02
KR20020090321A (ko) 2002-12-02
SK7332002A3 (en) 2003-05-02
AU4068502A (en) 2002-11-28
HU0201738D0 (https=) 2002-07-29
CA2387007A1 (en) 2002-11-24

Similar Documents

Publication Publication Date Title
CN1096461C (zh) 嘌呤衍生物和其作为抗凝剂的用途
CN1029613C (zh) 氨基甲酸肟酯和碳酸肟酯的制法
CN1136197C (zh) 新的哒嗪酮衍生物
CN1300114C (zh) 苯基吡啶甲酰哌嗪衍生物
CN1933834A (zh) 吲唑甲酰胺衍生物在制备用于治疗和预防疟疾的药物中的用途
CN1198807C (zh) 作为环加氧酶-2抑制剂的5-芳基-1h-1,2,4-三唑化合物及含有它们的药物组合物
CN1934092A (zh) 非核苷逆转录酶抑制剂
CN1921863A (zh) 免疫抑制剂化合物和组合物
CN1422273A (zh) 1,5-二取代-3,4-二氢-1H-嘧啶并[4,5-d]嘧啶二酮化合物和其在治疗CSBP/p38激酶介导的疾病中的用途
CN1234798A (zh) 环状氨基酸和环状羟基羧酸衍生物取代的苄脒衍生物和它们用作抗凝剂的用途
CN1161328A (zh) 氨烷基取代的苯并杂环化合物
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1265098A (zh) 抑制因子xa的杂环衍生物
CN1492762A (zh) 用作代谢调节剂的为丙二酸单酰辅酶a脱羧酶抑制剂的吡咯
CN1329613A (zh) 新的化合物
CN1144802A (zh) 哒嗪酮衍生物及其制备方法
CN1285825A (zh) 新的烯丙硫基哒嗪衍生物及其制备方法
CN1084178A (zh) 具抗病毒和抗癌活性的2′-脱氧-2′,2′-二氟(2,6,8-取代的)嘌呤核苷以及中间体
CN1390547A (zh) 对由局部缺血引发的组织损伤的治疗
US6730674B2 (en) Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
CN1347875A (zh) 新的环丁烯二酮化合物及其制备方法和含这些化合物的药物组合物
CN1191241C (zh) 用于抗充血性心力衰竭的哒嗪基苯基腙
CN88101782A (zh) 抗心律不齐药
CN1665508A (zh) 吡唑并[4,3-d]嘧啶类化合物的应用
CN1172478A (zh) 喹诺酮衍生物抗血栓形成药

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1050634

Country of ref document: HK